Document:

Exhibit 4.4

 

FIRST SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of June 4, 2014, between Sanmina Corporation, a Delaware corporation (the “Company”), the Notes Guarantors and U.S. Bank National Association, as trustee under the indenture referred to below (the “Trustee”).

 

W I T N E S S E T H

 

WHEREAS, the Company, the Notes Guarantors and the Trustee have entered into an indenture, dated as of May 10, 2011 (the “Indenture”);

 

WHEREAS, pursuant to the Indenture, the Company issued an aggregate principal amount of up to $500,000,000 of 7% Senior Notes due 2019 (the “Notes”);

 

WHEREAS, Section 902 of the Indenture provides that the Company and the Trustee may amend or supplement the Indenture with the consent of the Holders of at least a majority in aggregate principal amount of the Outstanding Notes (including consents obtained in connection with a tender offer or exchange offer for such Notes), with certain exceptions;

 

WHEREAS, pursuant to an Offer to Purchase and Consent Solicitation Statement, dated as of May 20, 2014 (as amended, the “Consent Solicitation”), the Company solicited and obtained consents from registered Holders of the Notes for amendments to the Indenture described therein (the “Consents”), such Consents having been obtained in connection with a tender offer for the Notes;

 

WHEREAS, Consents with respect to a majority in aggregate principal amount of the Outstanding Notes were given by the registered Holders of the Notes such that the amendments to be made pursuant to this Supplemental Indenture have been authorized in accordance with Section 902 of the Indenture as certified by the requisite officers of the Company;

 

WHEREAS, the Company and the Notes Guarantors hereby request that the Trustee execute this Supplemental Indenture, and the Company, the Notes Guarantors and the Trustee desire and have agreed to execute and deliver this Supplemental Indenture as herein provided, and all conditions necessary to authorize the execution and delivery of this Supplemental Indenture and to make it a valid and binding obligation of the Company and the Notes Guarantors have been done or performed.

 

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company, the Notes Guarantors and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows:

 

1.              CAPITALIZED TERMS.  Capitalized terms used and not otherwise defined herein shall have the meanings assigned to them in the Indenture.

 

2.              AMENDMENTS.

 

 

(a)         Section 101 (Definitions) of the Indenture is hereby amended to delete in their entirety all terms and their definitions for which all references are eliminated in the Indenture as a result of the amendments set forth in this Section 2 of this Supplemental Indenture if such terms are used solely in the sections that are deleted by the amendments.

 

(b)         Clauses (5) and (6) of Section 501(a) (Events of Default) of the Indenture are each hereby amended and restated in their entirety to read as follows:

 

“[Intentionally omitted].”

 

(c)          Clauses (3) and (4) of Section 801(a) (Company May Consolidate, etc., only on Certain Terms) of the Indenture are each hereby amended and restated in their entirety to read as follows:

 

“[Intentionally omitted].”

 

(d)         Section 1005 (Maintenance of Properties) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

(e)          Section 1006 (Payment of Taxes and Other Claims) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

(f)           Section 1007 (Maintenance of Insurance) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

(g)          Section 1008 (Limitation on Debt) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

(h)         Section 1009 (Limitation on Restricted Payments) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

(i)             Section 1010 (Limitation on Restrictions on Distributions from Restricted Subsidiaries) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

(j)            Section 1011 (Limitation on Liens) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

2

 

“[Intentionally omitted].”

 

(k)         Section 1013 (Limitation on Asset Sales) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

(l)             Section 1014 (Limitation on Transactions with Affiliates) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

(m)     Section 1015 (Repurchase at the Option of Holders upon a Change of Control) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

(n)         Section 1016 (Designation of Restricted and Unrestricted Subsidiaries) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

(o)         Section 1017 (Payments for Consent) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

(p)         Section 1019 (Available Information) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

(q)         Section 1022 (Covenants After Fall-Away Event) of the Indenture is hereby amended and restated in its entirety to read as follows:

 

“[Intentionally omitted].”

 

3.              EFFECTIVE TIME.  This Supplemental Indenture shall become effective upon execution by the Company and the Trustee; provided that, this Supplemental Indenture shall not become operative until the Company notifies the Trustee that it has accepted Notes for purchase tendered in the Consent Solicitation and that it has paid the Tender Offer Consideration (as defined in the Consent Solicitation).

 

4.              EFFECT OF HEADINGS.  The headings herein are for convenience only and shall not affect the construction hereof.

 

3

 

5.              SEPARABILITY CLAUSE.  In case any provision in this Supplemental Indenture or in the Notes shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

 

6.              GOVERNING LAW.  THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK.

 

7.              SUPPLEMENTAL INDENTURE SOLELY CORPORATE OBLIGATION.  No recourse for the payment of the principal of or premium, if any, or interest on the Notes, or for any claim based thereon or otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Company or the Notes Guarantors in the Indenture or this Supplemental Indenture or in any Note or Note Guarantee, or because of the creation of any indebtedness represented thereby, shall be had against any incorporator, stockholder, employee, agent, officer, or director or subsidiary, as such, past, present or future, of the Company or the Notes Guarantors or of any successor person or entity of any of them, either directly or through the Company or the Notes Guarantors or any successor person or entity of any of them, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly understood that all such liability is hereby expressly waived and released as a condition of, and as a consideration for, the execution of the Indenture, this Supplemental Indenture and the issue of the Notes and Note Guarantees.

 

8.              COUNTERPARTS.  This Supplemental Indenture may be executed in any number of counterparts, each of which shall be original; but such counterparts shall together constitute but one and the same instrument.

 

9.              THE TRUSTEE.  The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Company and the Notes Guarantors.

 

4

 

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed and attested, all as of the date first above written.

 

	
 
    	
The Company
    
	
 
    	
 
    
	
 
    	
SANMINA   CORPORATION
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Robert K. Eulau
    
	
 
    	
Name:
    	
Robert   K. Eulau
    
	
 
    	
Title:
    	
Chief   Financial Officer
    

 

[Signature page to Supplemental Indenture]

 

 

	
 
    	
Notes Guarantors
    
	
 
    	
 
    
	
 
    	
HADCO   CORPORATION
    
	
 
    	
HADCO   SANTA CLARA, INC.
    
	
 
    	
SANMINA-SCI   SYSTEMS HOLDINGS, INC.
    
	
 
    	
SCI   TECHNOLOGY, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Robert K. Eulau
    
	
 
    	
Name:
    	
Robert   K. Eulau
    
	
 
    	
Title:
    	
Chief   Financial Officer
    

 

[Signature page to Supplemental Indenture]

 

 

	
 
    	
The Trustee
    
	
 
    	
 
    
	
 
    	
U.S.   BANK NATIONAL ASSOCIATION, AS TRUSTEE
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Paula Oswald
    
	
 
    	
Name:
    	
Paula   Oswald
    
	
 
    	
Title:
    	
Vice   President
    

 

[Signature page to Supplemental Indenture]Exhibit 10.1

 

TETRALOGIC PHARMACEUTICALS CORPORATION

 

EXECUTIVE EMPLOYMENT
 AGREEMENT

 

THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of April 22, 2014 (“Effective Date”) by and between Richard Sherman a resident of Kilauea, Hawaii (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”).

 

Background

 

The Company desires to employ the Employee and the Employee desires to be employed by the Company, upon the terms and conditions hereinafter set forth.

 

IN CONSIDERATION of the foregoing and of the mutual covenants and obligations contained in this Agreement, the Employee and the Company, intending to be legally bound, hereby agree as follows:

 

1.                                      Employment and Term. The Company agrees to employ the Employee as the Senior Vice President General Counsel and Secretary. (such position, referred to herein as the Employee’s “Position”) for a period commencing April 22, 2014 and continuing until terminated in accordance with Section 5 of this Agreement (the “ Term”). Except as otherwise specifically set forth in this Agreement or specifically provided in the part time employment letter between Employee and Company dated November 13, 2012 (the “Employment Letter”) to survive termination thereof, the Employment Letter and all of its terms and conditions, shall terminate upon the Effective Date.

 

2.                                      Duties. During the Term, the Employee shall serve the Company faithfully and to the best of his ability and shall devote substantially all of his business time, attention, skill and efforts to the performance of the duties required by or appropriate for the Position. Subject to the oversight of the Chief Executive Officer and the Board, the Employee shall (i) lead all strategic and tactical legal initiatives for the Company and act as Secretary to the Board of Directors. (ii) He will participate in the strategic planning process and will implement new strategic initiatives as directed, and (iii) such duties and responsibilities as may be assigned to him from time to time by the Chief Executive Officer. The Employee shall perform such duties and responsibilities at the Company’s facility located in Malvern Pennsylvania at least 50% of the time or at such other location as may be established from time to time by the Company. The Employee shall report to the Chief Executive Officer of the Company.

 

3.                                      Other Business Activities. Except for the business activities set forth on Exhibit A or with the prior written consent of the  Company in its sole discretion, the Employee will not  engage, directly or indirectly, during the Term, in any other business activities or pursuits whatsoever, except activities in connection with charitable or civic activities, personal investments and serving as an executor, trustee or in other similar fiduciary capacity; provided that any such activities do not interfere with the performance of his responsibilities and obligations pursuant to this Agreement.

 

 

4.                                      Compensation. The Company shall pay the Employee, and the Employee hereby agrees to accept, as compensation for all services to be rendered to the Company and for the Employee’s intellectual property covenants and assignments and covenant not to compete, as provided in the Confidentiality Agreement, as defined in Section 6 hereof, the compensation set forth in this Section 4.

 

4.1                               Salary. The Company shall pay the Employee a base salary at the annual rate of Three Hundred Sixty Five Thousand Dollars ($365,000) (as the same may hereafter be adjusted, the “Salary”) during the term of this Agreement. The Salary shall be inclusive of all applicable income, social security and other taxes and charges that are required by law to be withheld by the Company (collectively, “Taxes”) and shall be paid and withheld in accordance with the Company’s normal payroll practice for its executive employees from time to time in effect. The Salary shall be subject to increase at the option and in the sole discretion of the Board or the Compensation Committee of the Board (the “Compensation Committee”) based upon the demonstrated performance of the Employee.

 

4.2                               Bonus. The Employee shall be eligible to be awarded an annual performance bonus of up to forty percent (40%) of Salary paid during the applicable period (“Bonus”), less the withholding of applicable Taxes, based on the achievement of performance objectives established by the Board for such year. Such bonus shall be determined by the Board or the Compensation Committee and shall be paid within seventy-five (75) days after the conclusion of each year. The Employee will also receive a $100,000 bonus effective with the date of hire, April 22, 2014 and is inclusive of his 2013 performance bonus.

 

4.3                               Equity Participation.

 

(a) Options

 

Stock Option Grant. On or before April 22, 2014, the Company will issue to the Employee a non- qualified stock option to purchase 100,000 shares of the Company’s common stock at an exercise price of fair market value per share as determined in good faith by the Board at the date of grant which will vest at the rate of 1/48th per month after the date of grant, subject to appropriate and proportionate adjustments for stock dividends, stock splits and other subdivisions and combinations of, and recapitalizations and like occurrences with respect to the Company’s common stock, (the “Option”).

 

The Options granted pursuant to this Section 4.3(a)(i)shall be exercisable for a period of ten (10) years from the date of grant and subject to the terms and provisions of the Company’s 2013 Equity Incentive Plan (as amended, the “Plan”) and to the Employee’s execution of a non-qualified stock option agreement which is substantially in the form customarily used by the Company with respect to the issuance of non-qualified stock options under the Plan to the Company’s employees and which contains additional terms not inconsistent with this Section 4.3 or the Plan that are determined to be appropriate by the Board. The Option will be fully exercisable in accordance with the vesting schedule set forth above,

 

 

provided, that in each case, the Employee continues to be an active full-time employee of the Company on the applicable vesting date; and provided further, that, if there shall occur a Change in Control (as defined in Section 4.3(c)) prior to the date on which the Option is fully vested, then the entire unvested portion of such stock, options or rights shall become immediately vested. In addition, the entire unvested portion of the Option shall become immediately vested upon the Employee’s death, Permanent Disability, Termination Without Cause or Termination for Good Reason (all as defined in Section 5 of this Agreement) if the Employee was an active full-time employee of the Company immediately before the applicable vesting termination event.

 

(b) Change in Control Defined. For purposes of this Agreement, the restricted stock agreement and/or a non-qualified stock option agreement which implements the issuance of common shares upon exercise of the Options, the term “Change in Control” shall mean, for purposes of the provisions of such restricted stock agreement and/or non-qualified stock option agreement which provide for the automatic acceleration of the vesting schedule for any Option, the happening of the earliest to occur of the events described in clauses (i), (ii), (iii) and (iv) of the definition of “Change in Control” contained in the Plan, except that, for such purposes, the “Original Issuance Exception” contained in clause (iv) of such definition shall be deemed to apply to original issuances by the Company of shares of its voting capital stock which are approved by at least a majority of the Board.

 

4.4                               Benefits. The Employee will be entitled to participate in all group life insurance, long-term disability, retirement, vacation and any and all other fringe benefit plans (other than bonus, incentive or equity-based compensation plans that may be sponsored by the Company from time to time) as are from time to time provided by the Company to its executives, subject to the provisions of such plans, including, without limitation, eligibility criteria and contribution requirements, as the same may be in effect from time to time (collectively referred to hereafter as “Benefits”).

 

4.5                               Reimbursement of Expenses.  During the course of employment, the Employee shall be reimbursed for items of travel, food and lodging and miscellaneous expenses reasonably incurred by him on behalf of the Company, provided that such expenses are incurred, documented and submitted to the Company, all in accordance with the reimbursement policies of the Company as in effect from time to time.

 

5.                                      Early Termination. The Employee’s employment hereunder may be terminated during the Term upon the occurrence of any one of the events described in this Section 5. Upon the effective date of such termination (the “Termination Date”), the Employee shall be entitled only to such compensation and benefits as described in this Section 5.

 

5.1                               Termination for Permanent Disability.

 

(a) Without limiting the Company’s right to terminate Employee pursuant to Section 5.2, 5.3 or 5.4 hereof, the Company may terminate the Employee’s employment hereunder at any time as a result of Employee’s Permanent Disability upon written notice to Employee. For purposes of this Agreement, a “Permanent Disability” shall have the same meaning as ascribed to such term (or a term of similar import) in the long-term disability insurance policy maintained by the Company for the Employee’s benefit, or if no such policy

 

 

exists, shall mean an illness, incapacity or a mental or physical condition that renders the Employee unable or incompetent to carry out the job responsibilities that the Employee held or the tasks that he was assigned at the time the disability commenced for at least 120 consecutive days or for shorter periods totaling 180 days in any twelve-month period, as determined by the Board and supported by the opinion of a physician. The Employee shall fully cooperate with the physician retained to furnish such opinion, including submitting to such examinations and tests as may be requested by the physician.

 

(b) In the event of a termination of Employee’s employment hereunder pursuant to Section 5.1(a), Employee will be entitled to receive all accrued and unpaid (as of the Termination Date) Salary, Benefits and Bonus, including payment prescribed under any disability plan or arrangement provided by the Company in which he is a participant or to which he is a party as an employee of the Company. Except as specifically set forth in this Section 5.1(b), the Company shall have no liability or obligation to Employee for compensation or benefits hereunder by reason of such termination.

 

5.2                               Termination by Death.  In the event that Employee dies during the Term, Employee’s employment hereunder shall be terminated thereby and the Company shall pay to Employee’s executors, legal representatives or administrators an amount equal to all accrued and unpaid (as of the Termination Date) Salary, Benefits and Bonus. Except as specifically set forth in this Section 5.2, the Company shall have no liability or obligation hereunder to Employee’s executors, legal representatives, administrators, heirs or assigns or any other person claiming under or through him by reason of Employee’s death, except that Employee’s executors, legal representatives or administrators will be entitled to receive the payment prescribed under any life insurance plan in which he is a participant as an employee of the Company.

 

5.3                               Termination for Cause; Voluntary Termination.

 

(a)         The Company may terminate Employee’s employment hereunder at any time for “Cause” immediately upon written notice to Employee. In addition, the Employee may voluntarily terminate his employment hereunder at any time following sixty (60) days prior written notice to the Board. For purposes of this Agreement, the term “Cause” shall mean, as determined by the Board in its sole discretion: (i) Employee’s failure or refusal to materially perform his duties hereunder or to follow a lawful directive of the Board; (ii) any material breach by the Employee of the terms of this Agreement or the Confidentiality Agreement (as defined below); (iii) other conduct of Employee involving any willful and material misconduct with respect to or against the Company or its property or any of its personnel and which causes material harm to the Company, its property or its personnel; or (iv) Employee being convicted of, or plea of guilty or no contest to, any felony or any crime involving moral turpitude. If termination for Cause is based upon Subsections (i), (ii) or (iii) of this Subsection (a) and the applicable breach, conduct or violation is capable of being cured, then the Employee shall have thirty (30) days following receipt of written notice to Employee from the Board specifying such failure in reasonable detail to cure such breach, conduct or violation.

 

(b)         In the event of a termination of Employee’s employment hereunder pursuant to Section 5.3(a), Employee shall be entitled to receive all accrued but unpaid (as of the Termination Date) Salary and Benefits. All Salary, Benefits and Bonuses shall cease at the time of such termination. Except as specifically set forth in this Section 5.3, the Company shall have no liability or obligation hereunder by reason of such termination. Vested Options shall be exercisable by Employee for a period of thirty (30) days after such termination.

 

 

5.4                               Termination Without Cause; Termination for Good Reason.

 

(a)                                 The Company may terminate Employee’s employment hereunder at any time, for any reason or for no reason, without Cause, effective upon the date designated by the Company upon ninety (90) days prior written notice to Employee. In addition, the Employee may voluntarily terminate his employment for Good Reason (as defined below) following ninety (90) days prior written notice to the Board.

 

(b)                                 If Employee’s employment is terminated pursuant to Section 5.4(a) at any time, then Employee shall be entitled to: (i) receive all accrued but unpaid (as of the Termination Date) Salary, Benefits and maximum target Bonus (as set forth in Section 4.2 of this Agreement) and (ii) the Company will continue to pay to the Employee in accordance with the Company’s regular payroll practices one hundred forty percent (140%) of his then current Salary in effect on the Termination Date during the twelve (12) month period immediately following the Termination Date, all subject to all tax withholding obligations, calculated on the basis of the Salary in effect at the Termination Date. The Company’s obligations to pay the amounts outlined in subsection (ii) of the first sentence of this Section 5.4(b) and in the immediately preceding sentence, as applicable, shall be contingent upon the Employee executing and not revoking a release of all claims pursuant to a Separation Agreement and Release substantially in the form attached hereto as Exhibit B. All Benefits and Bonuses shall cease at the time of such termination, subject to the terms of any benefit or compensation plan then in force and applicable to Employee. Except as specifically set forth in this Section 5.4(b), the Company shall have no liability or obligation hereunder by reason of such termination.

 

(c)                                  For purposes of this Agreement, the term “Good Reason” shall mean the earliest to occur of any of the following events that are not consented to by the Employee: (i) any substantial and adverse alteration by the Company of Employee’s functions, duties or responsibilities, or other material breach of this Agreement by Company, that is not remedied by the Company within thirty (30) days after receiving notice of such material alteration or breach; (ii) failure by Company or its successor, within thirty days after a Change Of Control to confirm Employee’s position as Chief Operating Officer of the Company or (iii) except as otherwise agreed in advance by Employee, requiring the Employee to be principally based (excluding all travel to perform the Employee’s services hereunder) at any office or location the site of which would result in a commuting distance of greater than 50 miles from Malvern, Pennsylvania; provided, further, that the Employee’s consent to any event which would otherwise constitute “Good Reason” shall be conclusively presumed if the Employee does not exercise his rights hereunder within thirty (30) days of the event.

 

6.                                      Confidentiality Agreement.  The terms and provisions of the Non- Competition, Non-Solicitation and Confidentiality Agreement between the Company and the Employee (the “Confidentiality Agreement”), dated as of December 1, 2012, and attached hereto as Exhibit C, shall be incorporated into this Agreement by reference for all purposes.

 

7.                                      Parachute Provisions.  Payments under this Agreement shall be made without regard to whether the deductibility of such payments (or any other payments) would be limited or precluded by Section 280G of the Internal Revenue Code of 1986, as amended (the

 

 

“Code”), and without regard to whether such payments would subject the Employee to the federal excise tax levied on certain “excess parachute payments” under Section 4999 of the Code; provided, however, that if the Total After-Tax Payments (as defined below) would be increased by the limitation or elimination of any amount payable under this Agreement, then the amount payable under this Agreement will be reduced to the extent necessary to maximize the Total After- Tax Payments. The determination of whether and to what extent payments under this Agreement are required to be reduced in accordance with the preceding sentence will be made by the Company’s independent auditors. In the event of any underpayment or overpayment under this Agreement (as determined after the application of this Section 7), the amount of such underpayment or overpayment will be immediately paid by the Company to the Employee or refunded by the Employee to the Company, as the case may be, with interest at the applicable federal rate provided for in Section 7872(f)(2) of the Code. For purposes of this Agreement, “Total After-Tax Payments” means the total of all “parachute payments” (as that term is defined in Section 280G(b)(2) of the Code) made to or for the benefit of the Employee (whether made hereunder or otherwise), after reduction for all applicable federal taxes (including, without limitation, the tax described in Section 4999 of the Code). Notwithstanding the foregoing, if so requested by the Employee, the Company shall use reasonable efforts to obtain the requisite approval by the stockholders of the Company in the manner contemplated by Q&A 7 of Treas. Reg. Section 1.280G, it being understood that the Company does not guarantee that such approval will be obtained. If the Company determines that such approval has been obtained, and such obligations of Q&A 7 of Treas. Reg. Section 1.280G have been met, all payments shall be made to Employee, without reduction.

 

8.                                      Representations, Warranties and Covenants of the Employee.

 

(a)                                 The Employee represents and warrants to the Company that:

 

(i)                                     There are no restrictions, agreements or understandings whatsoever to which the Employee is a party which would prevent or make unlawful the Employee’s execution of this Agreement or the Employee’s employment hereunder, or which is or would be inconsistent or in conflict with this Agreement or the Employee’s employment hereunder, or would prevent, limit or impair in any way the performance by the Employee of the obligations hereunder; and

 

(ii)                                  The Employee has disclosed to the Company all restraints, confidentiality commitments or other employment restrictions that he has with any other employer, person or entity.

 

(b)                                 The Employee covenants that in connection with his provision of services to the Company, he shall not breach any obligation (legal, statutory, contractual or otherwise) to any former employer or other person, including, but not limited to obligations relating to confidentiality and proprietary rights.

 

(c)                                  Upon and after his termination or cessation of employment with the Company and until such time as no obligations of the Employee to the Company hereunder exist, the Employee (i) shall provide the Confidentiality Agreement to any prospective employer or other person, entity or association engaged in the Field of Interest (as defined in the Confidentiality Agreement), with whom or which the Employee proposes to be

 

 

employed, affiliated, engaged, associated or to establish any business or remunerative relationship prior to the commencement thereof and (ii) shall notify the Company of the name and address of any such person, entity or association prior to his employment, affiliation, engagement, association or the establishment of any business or remunerative relationship.

 

9.                                 Non-Disparagement. The Company and Employee agree that, upon any termination of Employee’s employment for any reason: (i) the Company will not make any negative comments or disparaging remarks, in writing, orally or electronically about the Employee, and (ii) Employee will not make any negative comments or disparaging remarks, in writing, orally or electronically about the Company, or any of its officers, directors or employees.

 

10.                          Survival of Provisions. The provisions of this Agreement set forth in Sections 5 through 21 hereof and all other provisions of this Agreement that are intended to endure beyond the Term shall survive the termination of the Employee’s employment hereunder.

 

11.                          Successors and Assigns.  This Agreement shall inure to the benefit of and be binding upon the Company and the Employee and their respective successors, executors, administrators, heirs and/or assigns; provided that the Employee shall not make any assignment of this Agreement or any interest herein, by operation of law or otherwise, without the prior written consent of the Company.

 

12.                          Notice. Any notice hereunder by either party shall be given by personal delivery or by sending such notice by certified mail, return-receipt requested, or by overnight courier to the other party at its address set forth below or at such other address designated by notice in the manner provided in this section. Such notice shall be deemed to have been received upon the date of actual delivery if personally delivered, in the case of mailing, two (2) days after deposit with the U.S. mail, or, in the case of overnight courier, on the next business day.

 

	
 
    	
(i)
    	
if to the Company, to:
    
	
 
    	
 
    	
TetraLogic Pharmaceuticals
    
	
 
    	
 
    	
Corporation 343 Phoenixville Pike
    
	
 
    	
 
    	
Malvern, Pennsylvania 19355 
    
	
 
    	
 
    	
Attention: J. Kevin Buchi,
    
	
 
    	
 
    	
  President and CEO 
    
	
 
    	
 
    	
 
    
	
 
    	
(ii)
    	
if to the Employee, to: 
   Richard L. Sherman 
   4429 Kaluamakua Place, 
   PO Box 680,
    
	
 
    	
 
    	
Kilauea, HI 95754
    

 

13.                               Entire Agreement; Amendments.

 

(a) This Agreement, the Confidentiality Agreement and the restricted stock agreement(s) and/or nonqualified stock option agreement(s) referred to herein

 

 

contain the entire agreement and understanding of the parties hereto relating to the subject matter hereof, and merges and supersedes all prior and contemporaneous discussions, agreements and understandings of every nature between the parties hereto relating to the employment of the Employee with the Company (including without limitation, the Confidentiality, Non-Disclosure and Non-Use Agreement between the parties dated as of December 1, 2012).

 

(b)                       The Employee hereby acknowledges that (a) the sole shares, options, warrants, exit participation rights and other interests in the equity or any exit participation rights of the Employee with respect to the Company are the Options contemplated by Section 4.3 of this Agreement; and (b) the Employee has no other rights in the equity of, or to participate in the proceeds of any sale of or other transaction involving, the Company.

 

(c)                        This Agreement may not be changed or modified, except by an agreement in writing signed by each of the parties hereto.

 

14.                          Waiver. The waiver of the breach of any term or provision of this Agreement shall not operate as or be construed to be a waiver of any other or subsequent breach of this Agreement.

 

15.                          Governing Authority. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to the principles of conflicts of laws of any jurisdiction. The Employee agrees that the Company shall have the right to commence and maintain an action hereunder in the state and federal courts appropriate for the location at which the Company maintains its corporate offices, and the Employee hereby submits to the jurisdiction and venue of such courts.

 

16.                          Invalidity. If any provision of this Agreement shall be determined to be void, invalid, unenforceable or illegal for any reason, the validity and enforceability of all of the remaining provisions hereof shall not be affected thereby. If any particular provision of this Agreement or the Confidentiality Agreement shall be adjudicated to be invalid or unenforceable, such provision shall be deemed amended to delete therefrom the portion thus adjudicated to be invalid or unenforceable, such amendment to apply only to the operation of such provision in the particular jurisdiction in which such adjudication is made; provided that, if any provision contained in this Agreement or the Confidentiality Agreement shall be adjudicated to be invalid or unenforceable because such provision is held to be excessively broad as to duration, geographic scope, activity or subject, such provision shall be deemed amended by limiting and reducing it so as to be valid and enforceable to the maximum extent compatible with the applicable laws of such jurisdiction, such amendment only to apply with respect to the operation of such provision in the applicable jurisdiction in which the adjudication is made.

 

17.                          Section Headings. The section headings in this Agreement are for convenience only; they form no part of this Agreement and shall not affect its interpretation.

 

18.                          Number of Days. In computing the number of days for purposes of this Agreement, all days shall be counted, including Saturdays, Sundays and legal holidays; provided that,

 

 

if the final day of any time period falls on a Saturday, Sunday or day which is a legal holiday in the Commonwealth of Pennsylvania, then such final day shall be deemed to be the next day which is not a Saturday, Sunday or legal holiday.

 

19.                     Specific Enforcement; Extension of Period.

 

(a)                            The Employee acknowledges that the restrictions contained in the Confidentiality Agreement are reasonable and necessary to protect the legitimate interests of the Company and its affiliates and that the Company would not have entered into this Agreement in the absence of such restrictions. The Employee also acknowledges that any breach by him of the Confidentiality Agreement will cause continuing and irreparable injury to the Company for which monetary damages would not be an adequate remedy. The Employee shall not, in any action or proceeding to enforce any of the provisions of this Agreement or the Confidentiality Agreement, assert the claim or defense that an adequate remedy at law exists. In the event of such breach by the Employee, the Company shall have the right to enforce the provisions of the Confidentiality Agreement by seeking injunctive or other relief in any court, and this Agreement or the Confidentiality Agreement shall not in any way limit remedies of law or in equity otherwise available to the Company.

 

(b)                            The periods of time set forth in the Confidentiality Agreement shall not include, and shall be deemed extended by, any time required for litigation to enforce the relevant covenant periods, provided that the Company is successful on the merits in any such litigation. The “time required for litigation” is herein defined to mean the period of time from the earlier of the Employee’s first breach of such covenants or service of process upon the Employee through the expiration of all appeals related to such litigation.

 

20.                          Arbitration.  Subject to the last sentence of this Section 19, if any dispute arises over the terms of this Agreement between the parties to this Agreement, either Employee or Company may submit the dispute to binding arbitration within thirty (30) days after such dispute arises, to be governed by the evidentiary and procedural rules of the American Arbitration Association (Commercial Arbitration). Employee and Company shall mutually select one (1) arbitrator within ten (10) days after a dispute is submitted to arbitration. In the event that the parties do not agree on the identity of the arbitrator within such period, the arbitrator shall be selected by the American Arbitration Association. The arbitrator shall hold a hearing on the dispute at a location chosen by the Company, which shall be within fifteen (15) miles of the Company’s then current corporate offices, within thirty (30) days after having been selected and shall issue a written opinion within fifteen (15) days after the hearing. The arbitrator shall also decide on the allocation of the costs of the arbitration to the respective parties, but Employee and Company shall each be responsible for paying the fees of their own legal counsel, if legal counsel is obtained. Either Employee or Company, or both parties, may file the decision of the arbitrator as a final, binding and unappealable judgment in a court of appropriate jurisdiction. Notwithstanding the foregoing provisions of this Section 19 to the contrary, matters in which an equitable remedy or injunctive relief is sought by a party, including but not limited to the remedies referred to in Section 18 hereof, shall not be required to be submitted to arbitration, if the party seeking such remedy or relief objects thereto, but shall instead be subject to the provisions of Sections 14 and 18 hereof.

 

20.                          Counterparts. This Agreement may be executed in one or more

 

 

counterparts, each of which shall be deemed an original, and all of which together shall be deemed to be one and the same instrument.

 

21.                          Section 409A. All payments to be made upon a termination of employment under this Agreement will only be made upon a “separation from service” within the meaning of Section 409A of the Code. In no event may Employee, directly or indirectly, designate the calendar year of payment. To the maximum extent permitted under Section 409A of the Code and its corresponding regulations, the cash severance benefits payable under the Agreement are intended to meet the requirements of the short-term deferral exemption under Section 409A of the Code and the “separation pay exception” under Treas. Reg. §1.409A-1(b)(9)(iii). For purposes of the application of Treas. Reg. § 1.409A-1(b)(4)(or any successor provision), each payment in a series of payments to Employee will be deemed a separate payment. Notwithstanding anything in the Agreement to the contrary or otherwise, except to the extent any expense, reimbursement or in-kind benefit provided pursuant to the Agreement does not constitute a “deferral of compensation” within the meaning of Section 409A of the Code and its implementing regulations and guidance, (a) the expenses eligible for reimbursement or in-kind benefits provided to Employee must be incurred during the Term (or applicable survival period), (b) the amount of expenses eligible for reimbursement or in- kind benefits provided to Employee during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to Employee in any other calendar year, (c) the reimbursements for expenses for which Employee is entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred and (d) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.

 

[SIGNATURE PAGE FOLLOWS]

 

 

IN WITNESS WHEREOF, the parties have caused this Executive Employment Agreement to be executed the day and year first written above.

 

	
 
    	
TETRALOGIC PHARMACEUTICALS CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ J. K. Buchi
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
J. K. Buchi
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
CEO
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Richard L. Sherman
    
	
 
    	
 
    
	
 
    	
/s/ Richard L. Sherman
    

 

 

EXHIBIT A

 

Permitted Business Activities

 

Board member Immunomedics, Inc. 
 Board member Hawaii Biotech, Inc.

 

 

EXHIBIT B

 

Separation Agreement and Release

 

THIS SEPARATION AGREEMENT AND RELEASE (this “Agreement”) is made by and between Richard L. Sherman. (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”).

 

WHEREAS, the Employee and the Company entered into an Executive Employment Agreement dated April 22, 2014 (the “Employment Agreement”) that sets forth the terms and conditions of the Employee’s employment with the Company, including the circumstances under which the Employee is eligible to receive severance pay.

 

NOW, THEREFORE, the Employee and the Company each intending to be legally held bound, hereby agree as follows:

 

1.                                      Consideration.  In consideration for a release of claims and other promises and covenants set forth herein, the Company agrees to pay the Employee such consideration as is specified in Section 5.4(b) of the Employment Agreement in accordance with the terms and conditions of the Employment Agreement.

 

2.                                      Employee’s Release. The Employee on his own behalf and together with his heirs, assigns, executors, agents and representatives hereby generally releases and discharges the Company and its predecessors, successors (by merger or otherwise), parents, subsidiaries, affiliates and assigns, together with each and every of their present, past and future officers, managers, directors, shareholders, members, general partners, limited partners, employees and agents and the heirs and executors of same (herein collectively referred to as the “Releasees”) from any and all suits, causes of action, complaints, obligations, demands, common law or statutory claims of any kind, whether in law or in equity, direct or indirect, known or unknown (hereinafter “Claims”), which the Employee ever had or now has against the Releasees, or any one of them occurring up to and including the date of the this Agreement. Notwithstanding anything herein to the contrary, the Employee’s release is not and shall not be construed as a release of any future claim by the Employee against the Company, to the extent a claim may otherwise exist, for indemnity, contribution or cost of defense in connection with the Employee being made a party to a suit initiated by or on behalf of a third party, which suit is based, in whole or in part, upon the work performed by the Employee for the Company within the scope of the Employee’s position and duties with the Company, or any alleged misconduct by the Employee within the scope of the Employee’s former position and duties as an officer or employee of the Company. This release specifically includes, but is not limited to:

 

a.                                           any and all Claims for wages and benefits including, without limitation, salary, stock options, stock, royalties, license fees, health and welfare benefits, severance pay, vacation pay, and bonuses;

 

 

b.                                           any and all Claims for wrongful discharge, breach of contract, whether express or implied, and Claims for breach of implied covenants of good faith and fair dealing;

 

c.                                            any and all Claims for alleged employment discrimination on the basis of race, color, religion, sex, age, national origin, veteran status, disability and/or handicap, in violation of any federal, state or local statute, ordinance, judicial precedent or Employee order, including but not limited to claims for discrimination under the following statutes: Title VII of the Civil Rights Act of 1964, 42 U.S.C. §2000e et seq.;  the Civil Rights Act of 1866, 42 U.S.C. §1981; the Civil Rights Act of 1991; the Age Discrimination in Employment Act, as amended, 29 U.S.C. §621 et seq.; the Older Workers Benefit Protection Act 29 U.S.C. §§ 623, 626 and 630; the Rehabilitation Act of 1972, as amended, 29 U.S.C. §701 et seq.; the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.; the Family and Medical Leave Act of 1993, 29 U.S.C. §2601, et seq.;  the Fair Labor Standards Act, as amended, 29 U.S.C. §201, et seq.; the Fair Credit Reporting Act, as amended, 15 U.S.C. §1681, et seq.; and the Employee Retirement Income Security Act of 1974, as amended, 29 U.S.C. §1000, et seq.  (“ERISA”) or any comparable state statute or local ordinance;

 

d.                                           any and all Claims under any federal or state statute relating to employee benefits or pensions;

 

e.                                            any and all Claims in tort, including but not limited to, any Claims for assault, battery, misrepresentation, defamation, interference with contract or prospective economic advantage, intentional or negligent infliction of emotional distress, duress, loss of consortium, invasion of privacy and negligence; and

 

f.                                             any and all Claims for attorneys’ fees and costs.

 

3.                                      Acknowledgment. The Employee understands that the release of Claims contained in this Agreement extends to all of the aforementioned Claims and potential Claims which arose on or before the date of this Agreement, whether now known or unknown, suspected or unsuspected, and that this constitutes an essential term of this Agreement. The Employee further understands and acknowledges the significance and consequences of this Agreement and of each specific release and waiver, and expressly consents that this Agreement shall be given full force and effect to each and all of its express terms and provisions, including those relating to unknown and uncompensated Claims, if any, as well as those relating to any other Claims specified herein. The Employee hereby waives any right or Claim that the Employee may have to employment, reinstatement or re-employment with the Company.

 

4.                                      Confidentiality. The Employee shall not disclose or publicize the terms of this Agreement to any person or entity, except that the Employee may disclose the terms, and/or fact of this Agreement to immediate family members, the Employee’s accountants and attorneys and to others as strictly required by law. The Employee is specifically prohibited from disclosing the fact or terms of this Agreement to any current or former employee of the Releasees. The Employee further agrees that he shall be responsible for the Company’s attorney’s fees and costs, if it needs to file an action to enforce its rights under this paragraph, to the extent permitted by law. In the event that the Employee is requested or required (by oral

 

B-2

 

questions, interrogatories, requests for information or documents in a court or administrative proceeding, subpoena, civil investigative demand or other similar process) to disclose the terms of this Agreement, the Employee will endeavor in good faith to provide the Company prompt notice of any such request or requirement so that the Company may, at the Company’s expense, seek a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement. If in the absence of a protective order or other similar remedy or the receipt of a waiver from the Company, the Employee reasonably determines that disclosure of the terms of this Agreement is required to comply with such process or applicable law, the Employee may, without liability under this Agreement, disclose to the appropriate authority only that portion of the information which, on advice of counsel, he reasonably believes he is required to disclose.

 

5.                                      Remedies. All remedies at law or in equity shall be available to the Releasees for the enforcement of this Agreement. This Agreement may be pleaded as a full bar to the enforcement of any Claim that the Employee may assert against the Releasees.

 

6.                                      No Admission. Neither the execution of this Agreement by the Company, nor the terms hereof, constitute an admission by the Company of any liability to the Employee.

 

7.                                      Entire Agreement. This Agreement contains the entire agreement of the parties with respect to the subject matter hereof, and shall be binding upon their respective heirs, executors, administrators, successors and assigns. In the event there is any inconsistency between the terms of this Agreement and the Employment Agreement, the terms of this Agreement shall control.

 

8.                                      Severability. If any term or provision of this Agreement shall be held to be invalid or unenforceable for any reason, then such term or provision shall be ineffective to the extent of such invalidity or unenforceability without invalidating the remaining terms or provisions hereof, and such term or provision shall be deemed modified to the extent necessary to make it enforceable.

 

9.                                      Advice of Counsel: Revocation Period. The Employee is hereby advised to seek the advice of counsel prior to signing this Agreement. The Employee hereby acknowledges that the Employee is acting of his own free will, that he has been afforded a reasonable time to read and review the terms of this Agreement, and that he is voluntarily entering into this Agreement with full knowledge of its provisions and effects. The Employee further acknowledges that he has been given at least TWENTY-ONE (21) days within which to consider this Agreement and that he has SEVEN (7) days following his execution of this Agreement to revoke his acceptance, with this Agreement not becoming effective until the 7-day revocation period has expired. If the Employee elects to revoke his acceptance of this Agreement, the Employee must provide written notice of such revocation by certified mail (postmarked no later than seven days after the date the Employee accepted this Agreement) to:

 

B-3

 

	
 
    	
TetraLogic Pharmaceuticals Corporation
    
	
 
    	
343 Phoenixville Pike
    
	
 
    	
Malvern, Pennsylvania 19355
    
	
 
    	
Attention: Chief Executive officer
    
	
 
    	
Telecopier: (610) 889-9994
    

 

10.                               Employee’s Representation. The Employee represents and warrants that he has not assigned any claim that he purports to release hereunder and that he has the full power and authority to enter into this Agreement and bind each of the persons and entities that the Employee purports to bind. The Employee further represents and warrants that he is bound by, and agrees to remain bound by, his post-employment obligations set forth in the Employment Agreement.

 

11.                               Amendments. Neither this Agreement nor any term hereof may be changed, waived, discharged, or terminated, except by a written agreement signed by the parties hereto.

 

12.                               Governing Authority. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to the principles of conflicts of laws of any jurisdiction. The Employee agrees that the Company shall have the right to commence and maintain an action hereunder in the state and federal courts appropriate for the location at which the Company maintains its corporate offices, and the Employee hereby submits to the jurisdiction and venue of such courts.

 

13.                               Fees and Costs. The parties shall bear their own attorneys’ fees and costs.

 

14.                               Counterparts. This Agreement may be executed in counterparts.

 

15.                               Legally Binding. The terms of this Agreement contained herein are contractual, and not a mere recital.

 

[SIGNATURE PAGE FOLLOWS}

 

B-4

 

IN WITNESS WHEREOF, the Employee, acknowledging that he is acting of his own free will after having had the opportunity to seek the advice of counsel and a reasonable period of time to consider the terms of this Agreement and the Company, have caused the execution of this Agreement as of this day and year written below.

 

 

	
 
    	
 
    	
 
    
	
Richard L Sherman 
    	
 
    	
Witness:
    
	
 
    	
 
    	
 
    
	
Date:
    	
 
    	
 
    	
Date:
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
TETRALOGIC   PHARMACEUTICALS CORPORATION
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Name and Title:
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
 
    	
 
    	
 
    
								

 

B-5

 

EXHIBIT C

 

CONFIDENTIALITY, ASSIGNMENT OF INVENTIONS AND NON-COMPETITION AGREEMENT

 

IN CONSIDERATION of the undersigned’s (the “Employee”) employment by TetraLogic Pharmaceuticals Corporation or any of its subsidiaries or affiliates (collectively, the “Company”) and of the Company’s grant of certain stock options to the Employee, and intending to be legally bound, the Employee agrees to the following:

 

1.   Non-Disclosure And Non-Use Of Confidential Information.

 

(a)                                 The Employee shall, at all times during the term of the Employee’s employment with the Company and at all times thereafter, keep all Confidential Information (as defined below) secret and confidential and will not, directly or indirectly, disclose or use any of the Confidential Information, except as is strictly necessary in the course of the Employee’s performance of his or her assigned duties and in strict accordance with the policies, procedures and requirements established by the Company at any time and from time to time regarding the disclosure and use of Confidential Information.

 

(b)                                 As used in this Agreement, the term “Confidential Information” means all technical, scientific, financial, commercial, strategic and other information and data, without regard to form or medium, relating to the Company that is not generally known to the public. By way of illustration, Confidential Information includes, but is not limited to, the following kinds of information and data: research and development plans, strategies, methods, efforts and results; formulae, compositions, sequences, processes, cell lines, inventions, know-how and other technologies; patent protection and licensing strategies; computer codes and instructions; business and market studies; business and product development plans, strategies, efforts and results; personnel data; information relating to any of the Company’s actual and prospective customers, joint venture and collaborative research partners, licensees, licensors, consultants, agents, contractors and vendors and the nature and terms of the Company’s relationship with any of them; budgets, financial statements and financial projections; and any information provided by or on behalf of any third party to the Company under any obligation or expectancy of confidentiality.

 

(c)                                  Any information and data which becomes generally known to the public because of the Employee’s failure to abide by this Agreement will still be considered Confidential Information under this Agreement. Specific information comprising a part of any Confidential Information shall not be deemed to be in the public domain merely because it is embraced by more general information in the public domain. Failure to mark any of the Confidential Information as confidential or proprietary shall not affect its status as Confidential Information under this Agreement.

 

2.   Assignment and Ownership of Inventions.

 

(a) The Employee hereby irrevocably assigns to the Company all writings, reports, laboratory notebooks, works of authorship, inventions, discoveries, ideas, improvements, computer programs and instructions, formulae, compositions, sequences, processes, cell lines, know-how and other technologies that the Employee makes, conceives, discovers or develops or reduces to practice, either solely or jointly with any other person, at any time during the term of the Employee’s employment with the Company (or thereafter, if based upon or incorporating any Confidential Information), whether or not during working hours or at any of the Company’s facilities or at any other time or location, and whether upon the request or suggestion of the Company or otherwise, that relate to

 

 

or may in any way be useful in connection with any business now or hereafter carried on by the Company (collectively, the “Intellectual Work Product”) under all patent, copyright, trade secret and trademark laws and all other laws providing for the protection of intellectual property or similar rights. The Employee acknowledges that all Intellectual Work Product that is copyrightable will be considered a work made for hire under United States copyright laws. The Employee also hereby irrevocably assigns to the Company all claims to moral rights in any Intellectual Work Product, and to the extent such rights are not assignable, the Employee hereby waives all claims to such rights. The Employee shall promptly and fully disclose to the Company all Intellectual Work Product and maintain, on the Company’s behalf, any and all records thereof. The Employee shall have no claim for additional compensation for the Intellectual Work Product.

 

(b) The Employee shall, at all times during the term of his or her employment with the Company and at all times thereafter, assist the Company or its designee, at the Company’s expense, in acquiring and maintaining patent, copyright, trade secret, and trade mark and other analogous intellectual property protection upon, and confirming the Company’s title to, any Intellectual Work Product. The Employee’s assistance shall include, but not be limited to, making all lawful oaths and declarations, signing all documents, cooperating in all legal proceedings, and taking any and all other actions considered necessary or desirable by the Company to achieve these purposes. If the Company is unable after reasonable effort to secure the Employee’s signature on any of the documents referenced in this Section 2(b), whether because of the Employee’s physical or mental incapacity or for any other reason whatsoever, the Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Employee’s agent and attorney-in-fact, to act for and in the Employee’s behalf and stead to sign and file any such documents and to do all other lawfully permitted acts to further the prosecution and issuance and securing of any such intellectual property protection, with the same legal force and effect as if signed or done by the Employee. This power of attorney is coupled with an interest and is not revocable.

 

3.   Non-Competition and Non-Solicitation. During the term of the Employee’s employment with the Company and for a period of [one (1)] year after the termination of such employment, the Employee will not, directly and indirectly, for or on behalf of himself or herself or any person or entity other than the Company, do any one or more of the following anywhere in the world:

 

(a)                                 have any financial interest in, or provide any services of any kind for, (i) any business involved in the research, development, manufacture or sale of therapeutic or diagnostic products which are intended to function based on the activation or inhibition of apoptotic events or through direct modulation of the activation or inhibition of apoptosis proteins, eIF-5A and any other targets that activate or inhibit apoptotic events chosen to be pursued by the Company at any time during the term of the Employee’s employment, or (ii) any business which, at the time of termination of the Employee’s employment, is under meaningful consideration or active development and about which the Employee had access to Confidential Information or on which the Employee worked in any capacity at any time while employed with the Company (the businesses referred to in the foregoing clauses (i) and (ii), collectively, the “Field of Interest”);

 

(b)                                 solicit, for the purpose of competing in the Field of Interest, (i) any joint venture or collaborative research partners, licensees, licensors, consultants, agents, contractors or vendors of the Company, or (ii) any prospective joint venture or collaborative research partners, licensees, licensors, consultants, agents, contractors or vendors with respect to which the Company has developed or made a presentation regarding any of the research, development, manufacture, sale, use or

 

2

 

exploitation of products, services or processes in the Field of Interest at any time during the [three (3)] year period before the termination of the Employee’s employment;

 

(c)                                  solicit sales from any of the Company’s customers for any product or service which competes in the Field of Interest;

 

(d)                                 solicit, recruit or hire any person who is an employee or consultant of the Company during the period of such person’s employment or engagement with the Company and during the six (6) month period after the termination of such employment or engagement; and

 

(e)                                  entice any joint venture or collaborative research partner, licensee, licensor, consultant, agent, contractor or vendor of the Company to cease its business relationship with the Company.

 

Nothing in this Section 3 shall preclude the Employee from (1) purchasing or owning any equity securities in any company if such equity security is publicly traded so long as the Employee’s holdings do not exceed three percent (3%) of the issued and outstanding equity securities of that company or (2) serving on the board of directors of a publicly traded company if the Employee’s responsibilities do not include input or direction in the Field of Interest.

 

The Employee recognizes and acknowledges that the types of activities (which include employment activities) prohibited by this Section 3 are narrow and reasonable in relation to the skills which represent the Employee’s principal salable asset both to the Company and other prospective employers and in view of the confidential position to be held by the Employee with the Company. The Employee further recognizes and acknowledges that the specific but broad geographical scope of the provisions of this Section 3 is reasonable, legitimate and fair to the Employee in light of the Company’s need to perform its research and to develop, market and sell its products and services in a large geographic area to have a sufficient customer base to make the Company’s business profitable and in light of the limited restrictions on the type of activities prohibited by this Section 3 compared to the types of activities for which the Employee is qualified to earn a livelihood.

 

4.   Company Property. The Employee will not remove or transfer from any of the Company’s facilities any materials or property of the Company (including, without limitation, those containing any Confidential Information), except as is strictly necessary in the course of the Employee’s performance of his or her assigned duties and in strict accordance with the policies, procedures and requirements established by the Company at any time and from time to time regarding the removal and transfer of such materials and property. Promptly upon the Company’s request and, in any event promptly upon the termination of the Employee’s employment, the Employee shall return all materials and property of the Company that are in the Employee’s possession or control and the Employee shall not retain any copies of any such materials and property.

 

5.   Equitable Relief: Attorneys’ Fees. The Employee acknowledges that irreparable harm will result to the Company in the event of the Employee’s breach, or threatened breach, of any of the provisions of this Agreement and that remedies at law for a breach of this Agreement would be inadequate. If the Employee breaches or threatens to breach any provision of this Agreement, then the Company will be entitled, as a matter of right, to specific performance and/or injunctive relief without any requirement to post a bond as a condition to remedy any such breach. Such remedy shall not be deemed to be the exclusive remedy for any such breach of this Agreement but shall be in addition to all other rights and remedies to which the Company may be entitled. If the Company prevails in any action

 

3

 

or proceeding brought to enforce this Agreement, then the Company will be entitled to recover from the Employee all reasonable attorneys’ fees, costs and disbursements incurred by the Company in connection with such action or proceeding. The Employee further agrees that no failure or delay by the Company, its agents, or representatives in exercising any right, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power or privilege under this Agreement.

 

6.   No Restrictions. The Employee represents and warrants to the Company that:

 

(a)  there are no restrictions, agreements or understandings to which the Employee is a party or bound which would prevent, limit or impair the right of the Employee to enter into this Agreement, to be employed by the Company, or the Employee’s performance of his or her obligations under this Agreement or duties as a Employee;

 

(b)  all information furnished or to be furnished by the Employee to the Company in connection with the Employee’s employment with the Company is or will be true and complete in all respects; and

 

(c)  the Employee has disclosed to the Company all restraints, confidentiality commitments or other employment restrictions that he or she has with any other person, partnership, corporation, association or other entity.

 

7.   Compliance with Company Policies. The Employee shall not breach any obligation to any former employer or other person or entity including, but without limitation, obligations relating to confidentiality, noncompetition and proprietary rights in connection with the Employee’s provision of services to the Company. During the term of his or her employment, the Employee shall comply with all lawful policies, practices and procedures established at any time and from time to time by the Company.

 

8.   Notice of Obligations to Third Parties. Upon and after the termination of the Employee’s employment with the Company, the Employee shall notify the Company of the name and address of any each other person or entity with whom the Employee proposes to provide services (whether as an employee or otherwise) or establish any business or remunerative relationship before the Employee begins to provide such services or establish such relationship. The Company shall be entitled to provide a copy of this Agreement or any portion of this Agreement to any person or entity with, through or on behalf of which the Employee may propose to be employed, affiliated, engaged, associated or prepared to establish any business or remunerative relationship.

 

9.   Miscellaneous.

 

(a) Severability. Each provision of this Agreement is an independent provision. If a court of competent jurisdiction finds any particular provision of this Agreement to be indefinite, invalid, illegal or otherwise avoidable or unenforceable as applied to any circumstance, then the balance of this Agreement shall not fail on account of such finding and the application of the remaining provisions shall continue in full force and effect. However, if any provision of this Agreement should be determined by a court of competent jurisdiction to be unreasonable in duration, geographic area, or scope in any particular jurisdiction, then such provision is intended to and shall be deemed amended by limiting and reducing it so as to be valid and enforceable to the maximum extent compatible with the applicable laws of such jurisdiction, as determined by such court.

 

4

 

(b) Survival of Provisions; Amendment; Assignment. The Employee’s obligations under this Agreement shall survive the termination of the Employee’s employment with the Company for any reason or no reason and whether such termination is voluntary or involuntary. None of the provisions of this Agreement can be changed without a writing signed by each of the Employee and the Company. The Employee shall have no right or power to assign all or any portion of this Agreement. The Company may freely assign all or any portion of this Agreement.

 

(c) Complete Agreement. This Agreement contains the entire understanding between the Company and the Employee with respect to the subject matter of this Agreement and supersedes all prior oral or written communications, negotiations, understandings, or agreements.

 

(d) Governing Law; Choice of Forum and Venue. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to the principles of conflicts of laws of any jurisdiction. The Company shall have the right to commence and maintain an action under this Agreement in the state and federal courts appropriate for the location at which the Company maintains its corporate offices, and the Employee hereby submits to the jurisdiction and venue of such courts. However, the Company may seek enforcement of this Agreement in any appropriate court and in any jurisdiction where the Employee is subject to personal jurisdiction and where venue is proper.

 

(e) No Waiver of Rights. Any waiver by the Company of any power or right under this Agreement must be in writing and signed by the Company to be enforceable. Any waiver by the Company shall not operate as a waiver of any other or future breach of this Agreement.

 

(f) Binding Obligation. This Agreement shall be binding upon the Employee and his or her heirs, executors and administrators and will inure to the benefit of the Company and its successors and assigns.

 

(g) NO EMPLOYMENT AGREEMENT. THIS AGREEMENT IS NOT, AND DOES NOT CONTAIN, A CONTRACT OF EMPLOYMENT OR A PROMISE OF CONTINUED EMPLOYMENT OR CONTINUED ASSOCIATION WITH THE COMPANY FOR ANY SPECIFIED TERM AND DOES NOT CHANGE THE AT-WILL NATURE OF THE EMPLOYEE’S EMPLOYMENT OR ASSOCIATION WITH THE COMPANY. EITHER OF THE EMPLOYEE OR THE COMPANY HAS THE RIGHT TO TERMINATE THE EMPLOYEE’S EMPLOYMENT OR ASSOCIATION AT ANY TIME AND FOR ANY REASON OR NO REASON.

 

IN WITNESS WHEREOF, the Employee has signed this Agreement as of the date written below.

 

	
 
    	
/s/   Richard L Sherman
    
	
 
    	
Employee   Signature
    
	
 
    	
 
    
	
 
    	
Richard   L Sherman
    
	
 
    	
Print   Employee Name
    
	
 
    	
 
    
	
 
    	
12-1-12
    
	
 
    	
Date   Signed
    

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]